Voy­ager bags a 'trans­for­ma­tion­al' $1.8B gene ther­a­py pact with Neu­ro­crine

Neu­ro­crine has bel­lied up to the deal ta­ble, snag­ging com­mer­cial rights to 4 gene ther­a­py de­vel­op­ment pro­grams at Voy­ager Ther­a­peu­tics — in­clud­ing their lead mid-stage treat­ment for Parkin­son-s dis­ease — for $165 mil­lion in cash split be­tween an up­front pay­ment and a $50 mil­lion eq­ui­ty stake, plus an­oth­er $1.5 bil­lion in mile­stone mon­ey.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER